There are 2949 resources available
LBA8_PR - Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Presenter: Ken Kato
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA9_PR - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
Presenter: Ronan Kelly
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA6_PR and LBA7_PR
Presenter: Elizabeth Smyth
Session: Presidential Symposium III
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Andres Cervantes
Session: Presidential Symposium III
Resources:
Webcast
Invited Discussant LBA8_PR and LBA9_PR
Presenter: Andres Cervantes
Session: Presidential Symposium III
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Andres Cervantes
Session: Presidential Symposium III
Resources:
Webcast
Welcome and Introduction
Presenter: Robert Coleman
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Evolution of diagnosis and classification of endometrial cancer and emergence of molecular classification
Presenter: Amit Oza
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Endometrial cancer as an attractive target for checkpoint inhibitor-based therapy
Presenter: Robert Coleman
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast
Monotherapy checkpoint inhibitor studies in recurrent endometrial cancer
Presenter: Renaud Sabatier
Session: GSK - Update on the evolving landscape for endometrial cancer treatment with Immunotherapy
Resources:
Webcast